Loading oncology approvals…
Loading oncology approvals…
Regulatory
Every record is one authority's decision for one application or DIN, shown with its jurisdiction, date, indication text as published and status. A molecule approved in one jurisdiction for one indication is not 'approved' in general.
RegulatoryDevelopment pipeline →Methodology
Coverage
Counts of records, not of drugs approved: one application can carry several dated records (original approval, efficacy supplements, one row per DIN in Canada).
Approval records
4,342
Distinct drugs
373
Records naming a cancer
982
Dated in the last 12 months
183
| Authority | Jurisdiction | Records | Drugs | In force | Withdrawn / cancelled | Last 12 months | Latest dated record |
|---|---|---|---|---|---|---|---|
| FDA | US | 2,343 | 304 | 2,343 | 0 | 115 | Sep 18, 2026 |
| Health Canada | CA | 1,538 | 273 | 979 | 559 | 48 | Sep 22, 2026 |
| EMA | EU | 461 | 246 | 386 | 75 | 20 | Sep 18, 2026 |
Data updated 17 hours agoSource updated unknown3 authority · jurisdiction pairs ingested
Feed
Latest approval date first; records without a date are listed last. Filters combine.
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| — | Decitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as DACOGEN (DIN 02490366) under ATC L01BC08 DECITABINE. Indications are not published in the Drug Product Database — see… | DIN02490366 | approved | health-canada-dpd |
| — | Abiraterone Acetate | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEVA-ABIRATERONE (DIN 02487446) under ATC L02BX03 ABIRATERONE. Indications are not published in the Drug Product… | DIN02487446 | withdrawnsource: Cancelled Pre Marketsince Jan 13, 2026 | health-canada-dpd |
| — | Ibrutinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as IMBRUVICA (DIN 02486776) under ATC L01EL01 IBRUTINIB. Indications are not published in the Drug Product Database —… | DIN02486776 | approved | health-canada-dpd |
| — | Ibrutinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as IMBRUVICA (DIN 02486768) under ATC L01EL01 IBRUTINIB. Indications are not published in the Drug Product Database —… | DIN02486768 | approved | health-canada-dpd |
| — | Ibrutinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as IMBRUVICA (DIN 02486741) under ATC L01EL01 IBRUTINIB. Indications are not published in the Drug Product Database —… | DIN02486741 | approved | health-canada-dpd |
| — | Ibrutinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as IMBRUVICA (DIN 02486733) under ATC L01EL01 IBRUTINIB. Indications are not published in the Drug Product Database —… | DIN02486733 | approved | health-canada-dpd |
| — | Fulvestrant | Health Canada CA | cancer not stated in this record | Marketed in Canada as APO-FULVESTRANT (DIN 02486350) under ATC L02BA03 FULVESTRANT. Indications are not published in the Drug Product… | DIN02486350 | approved | health-canada-dpd |
| — | Arsenic Trioxide | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEVA-ARSENIC TRIOXIDE FOR INJECTION (DIN 02484366) under ATC L01XX27 ARSENIC TRIOXIDE. Indications are not published… | DIN02484366 | withdrawnsource: Cancelled Pre Marketsince Jul 29, 2021 | health-canada-dpd |
| — | Arsenic Trioxide | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEVA-ARSENIC TRIOXIDE FOR INJECTION (DIN 02484358) under ATC L01XX27 ARSENIC TRIOXIDE. Indications are not published… | DIN02484358 | withdrawnsource: Cancelled Pre Marketsince Jul 29, 2021 | health-canada-dpd |
| — | Bosutinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as BOSULIF (DIN 02483793) under ATC L01EA04 BOSUTINIB. Indications are not published in the Drug Product Database — see… | DIN02483793 | withdrawnsource: Cancelled Pre Marketsince Mar 31, 2025 | health-canada-dpd |
| — | Pemetrexed | Health Canada CA | cancer not stated in this record | Marketed in Canada as PEMETREXED DISODIUM FOR INJECTION USP (DIN 02482967) under ATC L01BA04 PEMETREXED. Indications are not published in… | DIN02482967 | approved | health-canada-dpd |
| — | Sodium Iodide 131 I | Health Canada CA | cancer not stated in this record | Marketed in Canada as SODIUM IODIDE I-131 SOLUTION U.S.P (ORAL) THERAPEUTIC (DIN 02482673) under ATC V10XA01 SODIUM IODIDE 131 I.… | DIN02482673 | withdrawnsource: Cancelled Pre Marketsince Jun 9, 2023 | health-canada-dpd |
| — | Sodium Iodide 131 I | Health Canada CA | cancer not stated in this record | Marketed in Canada as SODIUM IODIDE I-131 SOLUTION U.S.P (INJECTION) THERAPEUTIC (DIN 02482657) under ATC V10XA01 SODIUM IODIDE 131 I.… | DIN02482657 | withdrawnsource: Cancelled Pre Marketsince Jun 9, 2023 | health-canada-dpd |
| — | Pralatrexate | Health Canada CA | cancer not stated in this record | Marketed in Canada as FOLOTYN (DIN 02481855) under ATC L01BA05 PRALATREXATE%. Indications are not published in the Drug Product Database —… | DIN02481855 | approved | health-canada-dpd |
| — | Glatiramer | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEVA-GLATIRAMER ACETATE (DIN 02481510) under ATC L03AX13 GLATIRAMER ACETATE. Indications are not published in the… | DIN02481510 | approved | health-canada-dpd |
| — | Bortezomib | Health Canada CA | cancer not stated in this record | Marketed in Canada as BORTEZOMIB FOR INJECTION (DIN 02480263) under ATC L01XG01 BORTEZOMIB. Indications are not published in the Drug… | DIN02480263 | approved | health-canada-dpd |
| — | Bortezomib | Health Canada CA | cancer not stated in this record | Marketed in Canada as BORTEZOMIB FOR INJECTION (DIN 02480255) under ATC L01XG01 BORTEZOMIB. Indications are not published in the Drug… | DIN02480255 | approved | health-canada-dpd |
| — | Azacitidine | Health Canada CA | cancer not stated in this record | Marketed in Canada as NAT-AZACITIDINE (DIN 02480220) under ATC L01BC07 AZACITIDINE. Indications are not published in the Drug Product… | DIN02480220 | withdrawnsource: Cancelled Pre Marketsince May 11, 2023 | health-canada-dpd |
| — | Fluorouracil | Health Canada CA | cancer not stated in this record | Marketed in Canada as FLUOROURACIL INJECTION (DIN 02476754) under ATC L01BC02 FLUOROURACIL. Indications are not published in the Drug… | DIN02476754 | approved | health-canada-dpd |
| — | Fluorouracil | Health Canada CA | cancer not stated in this record | Marketed in Canada as FLUOROURACIL INJECTION (DIN 02476746) under ATC L01BC02 FLUOROURACIL. Indications are not published in the Drug… | DIN02476746 | approved | health-canada-dpd |
| — | Fluorouracil | Health Canada CA | cancer not stated in this record | Marketed in Canada as FLUOROURACIL INJECTION (DIN 02476738) under ATC L01BC02 FLUOROURACIL. Indications are not published in the Drug… | DIN02476738 | approved | health-canada-dpd |
| — | Fluorouracil | Health Canada CA | cancer not stated in this record | Marketed in Canada as FLUOROURACIL INJECTION (DIN 02476711) under ATC L01BC02 FLUOROURACIL. Indications are not published in the Drug… | DIN02476711 | approved | health-canada-dpd |
| — | Busulfan | Health Canada CA | cancer not stated in this record | Marketed in Canada as BUSULFAN FOR INJECTION (DIN 02475006) under ATC L01AB01 BUSULFAN. Indications are not published in the Drug Product… | DIN02475006 | approved | health-canada-dpd |
| — | Abiraterone Acetate | Health Canada CA | cancer not stated in this record | Marketed in Canada as APO-ABIRATERONE (DIN 02473917) under ATC L02BX03 ABIRATERONE. Indications are not published in the Drug Product… | DIN02473917 | approved | health-canada-dpd |
| — | Abiraterone Acetate | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEVA-ABIRATERONE (DIN 02473356) under ATC L02BX03 ABIRATERONE. Indications are not published in the Drug Product… | DIN02473356 | withdrawnsource: Cancelled Pre Marketsince Jan 8, 2026 | health-canada-dpd |
| — | Busulfan | Health Canada CA | cancer not stated in this record | Marketed in Canada as BUSULFAN INJECTION (DIN 02473127) under ATC L01AB01 BUSULFAN. Indications are not published in the Drug Product… | DIN02473127 | approved | health-canada-dpd |
| — | Pemetrexed | Health Canada CA | cancer not stated in this record | Marketed in Canada as PEMETREXED DISODIUM FOR INJECTION (DIN 02472619) under ATC L01BA04 PEMETREXED. Indications are not published in the… | DIN02472619 | approved | health-canada-dpd |
| — | Doxorubicin | Health Canada CA | cancer not stated in this record | Marketed in Canada as DOXORUBICIN HYDROCHLORIDE FOR INJECTION USP (DIN 02467240) under ATC L01DB01 DOXORUBICIN. Indications are not… | DIN02467240 | withdrawnsource: Cancelled Pre Marketsince Jul 14, 2026 | health-canada-dpd |
| — | Bortezomib | Health Canada CA | cancer not stated in this record | Marketed in Canada as BORTEZOMIB FOR INJECTION (DIN 02467011) under ATC L01XG01 BORTEZOMIB. Indications are not published in the Drug… | DIN02467011 | approved | health-canada-dpd |
| — | Docetaxel | Health Canada CA | cancer not stated in this record | Marketed in Canada as TARO-DOCETAXEL (DIN 02465655) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database… | DIN02465655 | withdrawnsource: Cancelled Pre Marketsince Jul 11, 2022 | health-canada-dpd |
| — | Docetaxel | Health Canada CA | cancer not stated in this record | Marketed in Canada as TARO-DOCETAXEL (DIN 02465647) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database… | DIN02465647 | withdrawnsource: Cancelled Pre Marketsince Jul 11, 2022 | health-canada-dpd |
| — | Docetaxel | Health Canada CA | cancer not stated in this record | Marketed in Canada as TARO-DOCETAXEL (DIN 02465531) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database… | DIN02465531 | withdrawnsource: Cancelled Pre Marketsince Jul 11, 2022 | health-canada-dpd |
| — | Fulvestrant | Health Canada CA | cancer not stated in this record | Marketed in Canada as ACT FULVESTRANT (DIN 02463075) under ATC L02BA03 FULVESTRANT. Indications are not published in the Drug Product… | DIN02463075 | withdrawnsource: Cancelled Pre Marketsince Apr 23, 2020 | health-canada-dpd |
| — | Necitumumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as PORTRAZZA (DIN 02462478) under ATC L01FE03 NECITUMUMAB. Indications are not published in the Drug Product Database —… | DIN02462478 | withdrawnsource: Cancelled Pre Marketsince Jul 22, 2021 | health-canada-dpd |
| — | Anastrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as DOM-ANASTROZOLE (DIN 02459191) under ATC L02BG03 ANASTROZOLE. Indications are not published in the Drug Product… | DIN02459191 | withdrawnsource: Cancelled Pre Marketsince Feb 13, 2026 | health-canada-dpd |
| — | Elotuzumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as EMPLICITI (DIN 02455927) under ATC L01FX08 ELOTUZUMAB. Indications are not published in the Drug Product Database —… | DIN02455927 | withdrawnsource: Cancelled Pre Marketsince Dec 12, 2023 | health-canada-dpd |
| — | Elotuzumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as EMPLICITI (DIN 02455919) under ATC L01FX08 ELOTUZUMAB. Indications are not published in the Drug Product Database —… | DIN02455919 | withdrawnsource: Cancelled Pre Marketsince Dec 12, 2023 | health-canada-dpd |
| — | Temozolomide | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEMOZOLOMIDE CAPSULES (DIN 02455757) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug… | DIN02455757 | withdrawnsource: Cancelled Pre Marketsince Apr 23, 2021 | health-canada-dpd |
| — | Temozolomide | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEMOZOLOMIDE CAPSULES (DIN 02455749) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug… | DIN02455749 | withdrawnsource: Cancelled Pre Marketsince Apr 23, 2021 | health-canada-dpd |
| — | Pemetrexed | Health Canada CA | cancer not stated in this record | Marketed in Canada as PEMETREXED (DIN 02455498) under ATC L01BA04 PEMETREXED. Indications are not published in the Drug Product Database —… | DIN02455498 | approved | health-canada-dpd |
| — | Pemetrexed | Health Canada CA | cancer not stated in this record | Marketed in Canada as PEMETREXED (DIN 02455528) under ATC L01BA04 PEMETREXED. Indications are not published in the Drug Product Database —… | DIN02455528 | approved | health-canada-dpd |
| — | Gemcitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as GEMCITABINE INJECTION (DIN 02455382) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug Product… | DIN02455382 | approved | health-canada-dpd |
| — | Pemetrexed | Health Canada CA | cancer not stated in this record | Marketed in Canada as PEMETREXED DISODIUM FOR INJECTION (DIN 02454637) under ATC L01BA04 PEMETREXED. Indications are not published in the… | DIN02454637 | withdrawnsource: Cancelled Pre Marketsince Aug 1, 2019 | health-canada-dpd |
| — | Pemetrexed | Health Canada CA | cancer not stated in this record | Marketed in Canada as PEMETREXED DISODIUM FOR INJECTION (DIN 02454629) under ATC L01BA04 PEMETREXED. Indications are not published in the… | DIN02454629 | withdrawnsource: Cancelled Pre Marketsince Aug 1, 2019 | health-canada-dpd |
| — | Pemetrexed | Health Canada CA | cancer not stated in this record | Marketed in Canada as PEMETREXED DISODIUM FOR INJECTION (DIN 02454610) under ATC L01BA04 PEMETREXED. Indications are not published in the… | DIN02454610 | withdrawnsource: Cancelled Pre Marketsince Aug 1, 2019 | health-canada-dpd |
| — | Oxaliplatin | Health Canada CA | cancer not stated in this record | Marketed in Canada as OXALIPLATIN INJECTION (DIN 02454084) under ATC L01XA03 OXALIPLATIN. Indications are not published in the Drug Product… | DIN02454084 | approved | health-canada-dpd |
| — | Bortezomib | Health Canada CA | cancer not stated in this record | Marketed in Canada as BORTEZOMIB FOR INJECTION (DIN 02453487) under ATC L01XG01 BORTEZOMIB. Indications are not published in the Drug… | DIN02453487 | withdrawnsource: Cancelled Pre Marketsince Apr 21, 2021 | health-canada-dpd |
| — | Methotrexate | Health Canada CA | cancer not stated in this record | Marketed in Canada as AURO-METHOTREXATE TABLETS (DIN 02448165) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug… | DIN02448165 | approved | health-canada-dpd |
| — | Oxaliplatin | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEVA-OXALIPLATIN INJECTION (DIN 02446227) under ATC L01XA03 OXALIPLATIN. Indications are not published in the Drug… | DIN02446227 | withdrawnsource: Cancelled Pre Marketsince Jul 29, 2021 | health-canada-dpd |
| — | Docetaxel | Health Canada CA | cancer not stated in this record | Marketed in Canada as ACT DOCETAXEL 40 MG/ML (DIN 02444410) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product… | DIN02444410 | withdrawnsource: Cancelled Pre Marketsince Jul 24, 2020 | health-canada-dpd |
A record is one authority's decision for one application/DIN; the same molecule appears once per jurisdiction and indication. Health Canada DPD does not publish indications — its records state the brand, DIN and ATC class only, and a cancelled or dormant DIN is the status of one product, not of the molecule. FDA cancer mappings come from label text and are flagged probabilistic on the drug page.